Published 6 days ago • loading... • Updated 5 days ago

Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer

Summary

(MedPage Today) -- SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated analyses of the CheckMate...

5 Articles

All

Left

Center

Right

MedPage Today

Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer

(MedPage Today) — SAN FRANCISCO — Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated analyses of the CheckMate… Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114247 Author : Publish date : 2025-02-17 18:00:00 Copyright for syndicated content belongs to the linked Source.

6 days ago·New York, United States

Read Full Article

urologytime.com

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

5 days ago

Read Full Article

Pharmacy Times

Data Support Adjuvant Nivolumab for High-Risk MIUC, Regardless of Prior Chemotherapy

Nivolumab demonstrated a sustained disease-free survival benefit over placebo in high-risk muscle-invasive urothelial carcinoma (MIUC).

6 days ago

Read Full Article

curetoday.com

mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of bladder tumor was beneficial.

6 days ago

Read Full Article

Medical Xpress

Radiation plus combination immunotherapy may help preserve bladder in some patients with cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial published in Clinical Cancer Research.

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year